Rigel Announces Post-hoc Data Analysis of TAVALISSE® in Adult Patients with Immune Thrombocytopenia Published in the British Journal of Haematology
- Monday, July 27, 2020, 7:02
- Finance
- Add a comment
SOUTH SAN FRANCISCO, Calif., July 27, 2020 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that a paper presenting a post-hoc data analysis of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, as well as accompanying commentary have been published in the…
About the Author
adminasapcorp has written 41552 stories on this site.